IL228906D0 - Quinazoline derivatives for the treatment of viral infections and further diseases - Google Patents

Quinazoline derivatives for the treatment of viral infections and further diseases

Info

Publication number
IL228906D0
IL228906D0 IL228906A IL22890613A IL228906D0 IL 228906 D0 IL228906 D0 IL 228906D0 IL 228906 A IL228906 A IL 228906A IL 22890613 A IL22890613 A IL 22890613A IL 228906 D0 IL228906 D0 IL 228906D0
Authority
IL
Israel
Prior art keywords
treatment
quinazoline derivatives
viral infections
further diseases
diseases
Prior art date
Application number
IL228906A
Other languages
Hebrew (he)
Other versions
IL228906A (en
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP11166538 priority Critical
Priority to PCT/EP2012/059234 priority patent/WO2012156498A1/en
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of IL228906D0 publication Critical patent/IL228906D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44849923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL228906(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IL228906A publication Critical patent/IL228906A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

This invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy of disorders in which the modulation of toll - like - receptors is involved.
IL228906A 2011-05-18 2013-10-16 Quinazoline derivatives for the treatment of viral infections and further diseases IL228906A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP11166538 2011-05-18
PCT/EP2012/059234 WO2012156498A1 (en) 2011-05-18 2012-05-18 Quinazoline derivatives for the treatment of viral infections and further diseases

Publications (2)

Publication Number Publication Date
IL228906D0 true IL228906D0 (en) 2013-12-31
IL228906A IL228906A (en) 2017-08-31

Family

ID=44849923

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228906A IL228906A (en) 2011-05-18 2013-10-16 Quinazoline derivatives for the treatment of viral infections and further diseases

Country Status (29)

Country Link
US (1) US8916575B2 (en)
EP (1) EP2709989B8 (en)
JP (1) JP6050329B2 (en)
KR (2) KR102119700B1 (en)
AU (1) AU2012258220B2 (en)
BR (1) BR112013029537A2 (en)
CA (1) CA2835229C (en)
CL (1) CL2013003313A1 (en)
CY (1) CY1120429T1 (en)
DK (1) DK2709989T3 (en)
EA (1) EA028254B1 (en)
ES (1) ES2663601T3 (en)
HR (1) HRP20180447T1 (en)
HU (1) HUE036220T2 (en)
IL (1) IL228906A (en)
LT (1) LT2709989T (en)
ME (1) ME02986B (en)
MX (1) MX347966B (en)
MY (1) MY166557A (en)
NO (1) NO2709989T3 (en)
NZ (1) NZ616642A (en)
PL (1) PL2709989T3 (en)
PT (1) PT2709989T (en)
RS (1) RS57023B1 (en)
SG (1) SG194852A1 (en)
SI (1) SI2709989T1 (en)
UA (1) UA114476C2 (en)
WO (1) WO2012156498A1 (en)
ZA (1) ZA201308746B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101481164B1 (en) * 2008-01-30 2015-01-09 주식회사 미래셀바이오 Method of manufacturing induced pluripotent stem cell originated from somatic cell
PL3330257T3 (en) 2011-04-08 2020-06-15 Janssen Sciences Ireland Unlimited Company Pyrimidine derivatives for the treatment of viral infections
WO2013068438A1 (en) 2011-11-09 2013-05-16 Janssen R&D Ireland Purine derivatives for the treatment of viral infections
PL2872515T3 (en) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
BR112015007586A2 (en) 2012-10-10 2017-07-04 Janssen Sciences Ireland Uc pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
BR112015011036A2 (en) * 2012-11-16 2017-07-11 Janssen Sciences Ireland Uc heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
AU2014220717B2 (en) 2013-02-21 2018-03-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
PL2978429T3 (en) 2013-03-29 2017-08-31 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
AU2014270418B2 (en) 2013-05-24 2017-11-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
AU2014301089B2 (en) 2013-06-27 2018-10-04 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SG10201804306VA (en) 2013-07-30 2018-06-28 Janssen Sciences Ireland Uc THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
CR20170395A (en) * 2015-03-04 2017-11-07 Gilead Sciences Inc Modulatory compounds toll-like receptor
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
PE20181451A1 (en) 2015-12-15 2018-09-12 Gilead Sciences Inc Neutralizing antibodies to the human immunodeficiency virus
BR102017010009A2 (en) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2017205078A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
CN109476675A (en) 2016-07-01 2019-03-15 爱尔兰詹森科学公司 For treating the dihydropyran and pyrimidine derivatives of viral infection
UY37374A (en) 2016-08-26 2018-03-23 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
JP2019529379A (en) * 2016-09-02 2019-10-17 ギリアード サイエンシーズ, インコーポレイテッド Toll-like receptor modulator compound
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
SG10201914029RA (en) 2016-10-14 2020-03-30 Precision Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
AR110768A1 (en) 2017-01-31 2019-05-02 Gilead Sciences Inc crystalline forms of Tenofovir alafenamida
JOP20180008A1 (en) 2017-02-02 2019-01-30 Gilead Sciences Inc Compounds for the treatment of hepatitis b virus infection
JPWO2018181420A1 (en) 2017-03-29 2020-02-06 大日本住友製薬株式会社 Vaccine adjuvant formulation
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
US20190192504A1 (en) 2017-08-22 2019-06-27 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
AU2018385693A1 (en) 2017-12-15 2020-06-18 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
TW201945003A (en) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
US20190309052A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TW202010503A (en) 2018-04-06 2020-03-16 捷克科學院有機化學與生物化學研究所 3’3’-cyclic dinucleotides
TW202005655A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
TW201945388A (en) 2018-04-12 2019-12-01 美商精密生物科學公司 Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
TW202002972A (en) 2018-04-19 2020-01-16 美商基利科學股份有限公司 PD-1/PD-L1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
US20200031801A1 (en) 2018-07-06 2020-01-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020010223A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020056008A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
US20200108071A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
AR012634A1 (en) * 1997-05-02 2000-11-08 Sugen Inc Quinazoline-based compound, famaceutica composition comprising it, to synthesize method, use, methods of modulating the function deserina / threonine protein kinase with said compound and in vitro method for identifying compounds that modulate said function
AU732361B2 (en) 1997-11-28 2001-04-26 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compounds
JP4342007B2 (en) * 1998-08-10 2009-10-14 住友化学株式会社 Quinazoline derivatives
JP4315300B2 (en) * 1998-08-10 2009-08-19 住友化学株式会社 Novel quinazoline derivatives
KR20060016817A (en) * 2003-06-20 2006-02-22 콜레이 파마시티컬 그룹, 인코포레이티드 Small molecule toll-like receptor (tlr) antagonists
AU2005304040B2 (en) * 2004-11-09 2009-04-23 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
PE20091236A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab Pyrimidine derivatives as immunomodulators TLR7

Also Published As

Publication number Publication date
EA028254B1 (en) 2017-10-31
HRP20180447T1 (en) 2018-04-20
CN103748081A (en) 2014-04-23
EP2709989B8 (en) 2018-04-18
EP2709989A1 (en) 2014-03-26
KR102038895B1 (en) 2019-10-31
SG194852A1 (en) 2013-12-30
NZ616642A (en) 2015-06-26
SI2709989T1 (en) 2018-04-30
MY166557A (en) 2018-07-16
BR112013029537A2 (en) 2017-01-24
IL228906A (en) 2017-08-31
MX347966B (en) 2017-05-18
AU2012258220B2 (en) 2017-01-19
PT2709989T (en) 2018-03-27
HUE036220T2 (en) 2018-06-28
EA201391719A1 (en) 2014-03-31
LT2709989T (en) 2018-04-10
JP6050329B2 (en) 2016-12-21
PL2709989T3 (en) 2018-06-29
US8916575B2 (en) 2014-12-23
ZA201308746B (en) 2016-01-27
NO2709989T3 (en) 2018-05-19
US20140073642A1 (en) 2014-03-13
CA2835229A1 (en) 2012-11-22
DK2709989T3 (en) 2018-04-09
KR102119700B1 (en) 2020-06-08
WO2012156498A1 (en) 2012-11-22
UA114476C2 (en) 2017-06-26
AU2012258220A1 (en) 2013-10-31
ES2663601T3 (en) 2018-04-16
JP2014516958A (en) 2014-07-17
CA2835229C (en) 2020-05-05
RS57023B1 (en) 2018-05-31
KR20140051849A (en) 2014-05-02
CL2013003313A1 (en) 2014-07-04
KR20190124337A (en) 2019-11-04
EP2709989B1 (en) 2017-12-20
CY1120429T1 (en) 2019-07-10
ME02986B (en) 2018-10-20
MX2013013448A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
HRP20191713T1 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
IL246117D0 (en) Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
CY1120885T1 (en) Pyrrolo [3,2-d] pyrimidine for treating viral infections and other diseases
PH12015502615B1 (en) Chemical compounds
IL243195D0 (en) Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
PH12015501385A1 (en) Autotaxin inhibitors
PH12015501806B1 (en) Novel benzopyran kinase modulators
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
IL231536A (en) Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015500073A1 (en) Macrocyclic purines for the treatment of viral infections
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
HK1207636A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
TN2014000298A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
HRP20180447T1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX2016003457A (en) Substituted aminopyrimidine compounds and methods of use.
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
SI2870157T1 (en) Selective pi3k delta inhibitors
EA201590931A1 (en) Heterocyclic substituted derivatives 2-amino-hinazoline for the treatment of viral infections
PH12015501964B1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2014002542A (en) Heterocyclic compounds and uses thereof.
NZ702458A (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed